MAGEA1 and neoplasm: When encountering tumor cells that were already recognized by MAGE-specific TCR T cells in the absence of DAC treatment, DAC treatment resulted either in a further increase in antigen-specific cytokine secretion (e.g., MAGE-A1 vs. MEL06.24) or did not further affect IFN-γ secretion (e.g., MAGE-A1 vs. MEL15.09b).